Tenax Therapeutics heads into its August 13 earnings report as one of the most dramatic single-week collapses in the biotech space, with a 90% price drop forcing a complete re-read of the positioning signals that surrounded it.
The stock's freefall is the dominant fact here. TENX closed at $1.375 on August 10, down 90% in a single day, 90% on the week, and 92% over the past month. That kind of move almost certainly reflects a binary clinical or regulatory event — the stock was trading at roughly $13 before the collapse. Against that backdrop, the short interest data tells a story of shorts building into what they anticipated: short interest has risen 147% over the past month to 34.8% of the free float, a level that was already elevated before the crash crystallised the bearish thesis. The put/call ratio has jumped to 0.79, nearly three standard deviations above its 20-day average of 0.40 — options traders had been rotating into puts for weeks, with the PCR climbing almost every session since late July. That wasn't coincidence; the defensive tilt in options was a leading signal that something binary was approaching.
The contradiction, and it is a striking one, is that the lending market never tightened the way you'd expect around a heavily shorted name heading into catastrophe. Availability remains extremely loose at 776% — meaning nearly eight shares are available to borrow for every one already borrowed — and cost to borrow is a negligible 0.46%, actually lower than it was a month ago when it touched 2.3%. That suggests shorts were not crowding into a scarce borrow pool; there was ample capacity throughout. The ORTEX short score of 42 is consistent with this — elevated SI, but no squeeze pressure, no tightness.
Institutional ownership tells a more nuanced story ahead of the print. FMR (Fidelity) reported holding nearly 3.9 million shares as of June 30, adding over 3.6 million shares in the most recent quarter — a significant new position built just weeks before the crash. BlackRock and State Street also added aggressively in Q2. Several specialist biotech funds including Perceptive Advisors, Stonepine Capital, and Logos Global Management built positions in Q1. These are not passive accumulations; the specialist holders in particular tend to trade on clinical conviction. Whether they held through the collapse or had already reduced is unknown from the available data, but the concentration of biotech-specialist money heading into the event is notable context.
The August 13 print will test whether any residual fundamental narrative survives after a 90% collapse — and specifically whether management can articulate a path forward for levosimendan that justifies re-engagement from the institutional base that was still building positions just weeks ago.
See the live data behind this article on ORTEX.
Open TENX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
